ZVSA - .8678 Up .0885 In pre-market on news out tis AM
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.